MA32505B1 - 5-alcynyl-pyrimidines - Google Patents

5-alcynyl-pyrimidines

Info

Publication number
MA32505B1
MA32505B1 MA33560A MA33560A MA32505B1 MA 32505 B1 MA32505 B1 MA 32505B1 MA 33560 A MA33560 A MA 33560A MA 33560 A MA33560 A MA 33560A MA 32505 B1 MA32505 B1 MA 32505B1
Authority
MA
Morocco
Prior art keywords
pyrimidine
alkynyl
relates
compounds
drug
Prior art date
Application number
MA33560A
Other languages
Arabic (ar)
English (en)
Inventor
Tobias Wunberg
Ralph Brueckner
Dirk Kessler
Oliver Kraemer
Darryl Mcconnell
Siegfried Schneider
Der Veen Lars Van
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40202900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32505(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32505B1 publication Critical patent/MA32505B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Laminated Bodies (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)

Abstract

La présente invention porte sur des composés représentés par la formule générale (i) dans laquelle r1 à r4 sont tels que définis dans la revendication 1, qui sont appropriés pour le traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale. L'invention porte également sur l'utilisation de ces composés pour la préparation d'un médicament doté des propriétés mentionnées ci-dessus.
MA33560A 2008-07-29 2011-01-26 5-alcynyl-pyrimidines MA32505B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161369 2008-07-29
PCT/EP2009/059763 WO2010012740A1 (fr) 2008-07-29 2009-07-28 5-alcynyl-pyrimidines

Publications (1)

Publication Number Publication Date
MA32505B1 true MA32505B1 (fr) 2011-07-03

Family

ID=40202900

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33560A MA32505B1 (fr) 2008-07-29 2011-01-26 5-alcynyl-pyrimidines

Country Status (25)

Country Link
US (1) US8916548B2 (fr)
EP (1) EP2323992B1 (fr)
JP (1) JP5599791B2 (fr)
KR (1) KR20110041536A (fr)
CN (1) CN102112450A (fr)
AR (1) AR072845A1 (fr)
AU (1) AU2009275957A1 (fr)
BR (1) BRPI0916679A2 (fr)
CA (1) CA2731909A1 (fr)
CL (1) CL2011000195A1 (fr)
CO (1) CO6341617A2 (fr)
DK (1) DK2323992T3 (fr)
EA (1) EA201100255A1 (fr)
EC (1) ECSP11010786A (fr)
ES (1) ES2597903T3 (fr)
HU (1) HUE029837T2 (fr)
IL (1) IL210343A0 (fr)
MA (1) MA32505B1 (fr)
MX (1) MX2011000729A (fr)
NZ (1) NZ590558A (fr)
PE (1) PE20110196A1 (fr)
PL (1) PL2323992T3 (fr)
TW (1) TW201010984A (fr)
UY (1) UY32009A (fr)
WO (1) WO2010012740A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5651110B2 (ja) 2008-07-29 2015-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
CA2731909A1 (fr) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh 5-alcynyl-pyrimidines
AR076332A1 (es) * 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
UY33199A (es) 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
US8618111B2 (en) * 2010-01-26 2013-12-31 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
US8466162B2 (en) * 2011-01-26 2013-06-18 Boehringer Ingelheim International Gmbh 5-alkynyl-pyridines
TW201245176A (en) * 2011-01-26 2012-11-16 Boehringer Ingelheim Int New 5-alkynyl-pyridines
EP2736514B1 (fr) * 2011-07-28 2017-10-18 Nerviano Medical Sciences S.r.l. Pyrimidinyl-pyrroles substitués alcynyle agissant comme inhibiteurs de kinase
UA110995C2 (uk) * 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
PL3080100T3 (pl) 2013-12-11 2023-03-06 Celgene Quanticel Research, Inc. Inhibitory lizyno-specyficznej demetylazy-1
HUE057895T2 (hu) 2014-05-01 2022-06-28 Celgene Quanticel Res Inc Lizinspecifikus demetiláz-1 inhibitorai
ES2935114T3 (es) * 2014-09-05 2023-03-01 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3832570A1 (de) * 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
JPH08504798A (ja) 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
US5622954A (en) 1994-05-11 1997-04-22 Fmc Corporation 5[W(substituted aryl)alkenylene and alkynylene]-2,4-diaminopyrimidines as pesticides
ATE293962T1 (de) 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
CA2528938A1 (fr) * 2003-06-13 2005-02-24 Zentaris Gmbh Composes presentant une activite inhibitrice de la phosphatidylinositol 3-kinase
EP1737462B1 (fr) 2003-12-24 2008-07-30 AstraZeneca AB Pyrimidines a activite tie2 (tek)
EP1761540B1 (fr) * 2004-05-13 2016-09-28 Icos Corporation Quinazolinones utilisees en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2006082371A1 (fr) 2005-02-01 2006-08-10 Astrazeneca Ab Dérivés de pyrimidine présentant une activité inhibitrice de tie2 (tek)
EP1863805A1 (fr) 2005-02-01 2007-12-12 AstraZeneca AB Derives de pyrimidine presentant une activite inhibitrice de tie2 (tek)
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
JP4993205B2 (ja) 2005-03-30 2012-08-08 塩野義製薬株式会社 チロシンキナーゼ阻害作用を有するピリミジン誘導体
US20080194552A1 (en) 2005-03-31 2008-08-14 Astrazeneca Ab Aminopyrimidine Derivatives With Tie2 Inhibiting Activity
AU2006302179C1 (en) * 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP2010501537A (ja) 2006-08-24 2010-01-21 アストラゼネカ アクチボラグ 増殖性障害の治療に有用なモルホリノピリミジン誘導体
CN106045965A (zh) 2006-12-29 2016-10-26 爱尔兰詹森科学公司 抑制hiv的5,6‑取代的嘧啶类化合物
EP2022785A1 (fr) 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines comme inhibiteurs de la kinase Tie2
CA2731909A1 (fr) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh 5-alcynyl-pyrimidines
UY33199A (es) 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.

Also Published As

Publication number Publication date
CA2731909A1 (fr) 2010-02-04
US8916548B2 (en) 2014-12-23
BRPI0916679A2 (pt) 2015-11-17
DK2323992T3 (en) 2016-10-31
PE20110196A1 (es) 2011-04-03
ES2597903T3 (es) 2017-01-24
UY32009A (es) 2010-02-26
AU2009275957A1 (en) 2010-02-04
WO2010012740A1 (fr) 2010-02-04
ECSP11010786A (es) 2011-02-28
PL2323992T3 (pl) 2017-01-31
KR20110041536A (ko) 2011-04-21
MX2011000729A (es) 2011-03-15
HUE029837T2 (en) 2017-04-28
US20110281838A1 (en) 2011-11-17
CL2011000195A1 (es) 2011-07-08
NZ590558A (en) 2012-12-21
EP2323992B1 (fr) 2016-07-20
JP2011529468A (ja) 2011-12-08
CO6341617A2 (es) 2011-11-21
AR072845A1 (es) 2010-09-22
EP2323992A1 (fr) 2011-05-25
TW201010984A (en) 2010-03-16
JP5599791B2 (ja) 2014-10-01
EA201100255A1 (ru) 2011-08-30
IL210343A0 (en) 2011-03-31
CN102112450A (zh) 2011-06-29

Similar Documents

Publication Publication Date Title
MA32811B1 (fr) Nouveaux composés
EA201201030A1 (ru) 5-алкинилпиримидины
MY153971A (en) Sulfonamides as trpm8 modulators
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
EA201170521A1 (ru) Новые соединения
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
WO2010034838A3 (fr) Nouveaux composés chimiques
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
EA201101330A1 (ru) Замещенные пиримидины, предназначенные для лечения рака
EA201171211A1 (ru) Производные оксадиазола
EA201100255A1 (ru) 5-алкинилпиримидины
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
WO2009124962A3 (fr) Sulfonamides
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
EA201100254A1 (ru) Новые соединения
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
MY149154A (en) Novel microbiocides
IN2012DN03846A (fr)
MX2010009837A (es) Tiazolil-dihidro-indazoles.
TN2011000531A1 (en) 5- alkynyl - pyridines
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
DE602008002598D1 (en) Cyclohexylderivate